Iron Triangle Partners LP Has $46.38 Million Position in AbbVie Inc. $ABBV

Iron Triangle Partners LP lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 19.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,326 shares of the company’s stock after selling 49,671 shares during the period. AbbVie comprises 6.6% of Iron Triangle Partners LP’s holdings, making the stock its 3rd biggest holding. Iron Triangle Partners LP’s holdings in AbbVie were worth $46,383,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. JPL Wealth Management LLC grew its holdings in shares of AbbVie by 2.5% in the 3rd quarter. JPL Wealth Management LLC now owns 28,344 shares of the company’s stock worth $6,563,000 after acquiring an additional 679 shares during the last quarter. Jain Global LLC purchased a new stake in shares of AbbVie during the third quarter valued at $5,436,000. Hamilton Wealth LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $4,915,000. Hilltop Holdings Inc. increased its stake in AbbVie by 4.8% in the 3rd quarter. Hilltop Holdings Inc. now owns 56,279 shares of the company’s stock worth $13,031,000 after purchasing an additional 2,573 shares in the last quarter. Finally, Hollow Brook Wealth Management LLC increased its stake in AbbVie by 6.2% in the 3rd quarter. Hollow Brook Wealth Management LLC now owns 3,531 shares of the company’s stock worth $818,000 after purchasing an additional 206 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.08% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV opened at $219.73 on Monday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $224.33 and its two-hundred day moving average is $224.79. The stock has a market cap of $388.51 billion, a PE ratio of 93.10, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analyst Ratings Changes

A number of analysts have commented on ABBV shares. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.